Objective: Alcohol is the most acknowledged risk factor for liver cirrhosis. Smoking is rarely considered to be a cause of liver cirrhosis even though a few studies have suggested the opposite. The aim of this study was to assess the independent effect of smoking on alcoholic liver cirrhosis and liver cirrhosis in general.
Materials And Methods: The authors used data from the Copenhagen City Heart Study including a cohort of 9889 women and 8590 men from the Danish general population. Smoking and covariates were assessed at four consecutive examinations in 1976-78, 1981-83, 1991-94 and 2001-03. Updated measures were used in the analyses. Information on incident cases of alcoholic liver cirrhosis and liver cirrhosis was obtained from national hospital registries. Data were analyzed by means of Cox regression.
Results: A total of 225 cases of alcoholic liver cirrhosis and 431 cases of liver cirrhosis occurred during follow-up. The hazard ratios (HR) of alcoholic liver cirrhosis was 3.9, 95% confidence interval (CI): 1.6, 9.4 for women and 1.6, 95% CI: 0.9, 3.0 for men smoking >10 g of tobacco per day compared with never-smokers. For liver cirrhosis, corresponding HRs were 2.2, 95% CI: 1.4, 3.4 for women and 1.4, 95% CI: 0.9, 2.2 for men. The HRs were adjusted for age, alcohol intake, education and body mass index.
Conclusions: Smoking was associated with an increased risk of liver cirrhosis independent of alcohol intake.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/00365521.2013.777469 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical outcomes of COVID-19 in patients with liver cirrhosis - a propensity-matched analysis from a multicentric Brazilian cohort.
BMC Infect Dis
January 2025
Universidade Federal de Minas Gerais, Av. Presidente Antônio Carlos, 6627, Belo Horizonte, Minas Gerais, Brazil.
Background: Cirrhosis has been pointed out as a clinical entity that leads to worse clinical prognosis in COVID-19 patients. However, this concept is controversial in the literature. We aimed to evaluate clinical outcomes by comparing patients with cirrhosis to those without cirrhosis in a Brazilian cohort.
View Article and Find Full Text PDFCirrhosis and complications hepatocellular carcinoma - expanding indications for immunotherapy.
Acta Clin Belg
January 2025
Brussels Health Campus, Department of Gastroenterology and Hepatology, University Hospital Brussels (UZ Brussel), Brussels, Belgium.
The incidence of hepatocellular carcinoma (HCC) is rising, with a shift towards Metabolic Dysfunction-associated Steatotic Liver Disease becoming the dominant risk factor in Western countries. Significant advances in treatment have broadened the range of available therapeutic options. For this reason, clinical decision-making, along with a multidisciplinary team approach, plays a crucial role in improving patient outcomes.
View Article and Find Full Text PDFA Case of Severe Hypocalcemia During JAK1/2 Inhibitor Therapy for Myelofibrosis in a Patient with Liver Cirrhosis.
Intern Med
January 2025
Department of Internal Medicine 1, Shimane University Faculty of Medicine, Japan.
We herein report a 56-year-old man with severe hypocalcemia during ruxolitinib therapy for myelofibrosis transitioning from JAK2 mutation-positive polycythemia vera. Blood transfusions were administered every one to two weeks for ruxolitinib-induced anemia. Blood tests revealed hypocalcemia with low TRACP-5b, 25-hydroxyvitamin D (25 (OH) D), and 1,25-dihydroxyvitamin D (1,25 (OH) D) levels within the lower reference range.
View Article and Find Full Text PDFDesign, synthesis and biological evaluation of Alisol B derivatives for potential treatment of non-alcoholic steatohepatitis.
Bioorg Chem
January 2025
State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201 China; University of Chinese Academy of Sciences, Beijing 100049 China. Electronic address:
Non-alcoholic fatty liver disease (NAFLD), also known as metabolic dysfunction- associated with fatty liver disease (MAFLD), is one of the most prevalent chronic liver diseases globally. NAFLD is characterized by the accumulation of liver fat unrelated to excessive alcohol consumption. Non-alcoholic steatohepatitis (NASH) is the disease progression of NAFLD and could develop into cirrhosis and hepatocellular carcinoma.
View Article and Find Full Text PDFReal-time control of radiofrequency ablation using three-dimensional ultrasound echo decorrelation imaging in normal and diseasedhuman liver.
Phys Med Biol
January 2025
Department of Biomedical Engineering, University of Cincinnati, UC Bioscience Center, 3159 Eden Ave., Cincinnati, Ohio, 45221, UNITED STATES.
Ultrasound echo decorrelation imaging can successfully monitor and control thermal ablation of animal liver and tumor tissue ex vivo and in vivo. However, normal and diseased human liver has substantially different physical properties that affect echo decorrelation. Here, effects of human liver tissue condition on ablation guidance by three-dimensional echo decorrelation imaging are elucidated in experiments testing closed-loop control of radiofrequency ablation (RFA) in normal and diseased human liver tissue ex vivo.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!